| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8124125 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(5 months from now) | |
| US9173847 | SALIX | Tablet comprising a fibrate |
Oct, 2024
(5 months from now) | |
| US8481078 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(5 months from now) | |
| US7658944 | SALIX | Solid dosage form comprising a fibrate |
Dec, 2024
(7 months from now) | |
Fenoglide is owned by Salix.
Fenoglide contains Fenofibrate.
Fenoglide has a total of 4 drug patents out of which 0 drug patents have expired.
Fenoglide was authorised for market use on 10 August, 2007.
Fenoglide is available in tablet;oral dosage forms.
Fenoglide can be used as use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, for reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia.
The generics of Fenoglide are possible to be released after 09 December, 2024.
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 10 August, 2007
Treatment: For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia; Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl...
Dosage: TABLET;ORAL
FENOGLIDE family patents
